International Journal of Clinical Research

Objective To analyze the medical value of using levosimendan combined with coenzyme Q10 in the treatment of dilated cardiomyopathy. Methods Sixty patients with dilated cardiomyopathy who received treatment between January 2023 and December 2023 were selected as the study subjects. All patients received basic treatment, with 30 in the control group receiving additional treatment with coenzyme Q10 and 30 in the observation group receiving additional treatment with levosimendan. The cardiac function and blood pressure indicators of the two groups of patients before and after treatment were compared. Results Before treatment, there was no statistically significant difference between the two groups of patients (P>0.05). After nursing, the HR of the observation group was lower than that of the control group, LVD was better than that of the control group, and blood pressure was better than that of the control group, with statistically significant differences (P<0.05). Conclusion The use of levosimendan combined with coenzyme Q10 in the treatment of dilated cardiomyopathy can improve cardiac function, lower blood pressure, and benefit patients.

Levosimendan; Coenzyme Q10 therapy; Dilated cardiomyopathy; Heart function; Myocardial cells; Myocardial contraction